URGN: UroGen Pharma Ltd. Ordinary Shares Company Profile & Statistics

About

UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company's product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen Pharma Ltd. is based in Ra'anana, Israel.

Info & Links

CEO

Elizabeth Barrett

Headquarters

400 Alexander Park Drive
Princeton, NJ 08540, UNITED STATES

Auditor

PricewaterhouseCoopers LLP

Share holders

Employees

235

UroGen Pharma Ltd. Ordinary Shares Statistics

Valuation Measures

Market Capitalization²

568.46M

Enterprise Value

585.46M

Enterprise Value/EBITDA(ttm)

-5.27

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

2.81

Price to Book(mrq)

9.84

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

89.63%

Operating Margin(ttm)

-129.11%

Profit Margin(ttm)

-154.00%

Return on Equity(ttm)

Return on Invested Capital(ttm)

-133.32%

Return on Assets(ttm)

-47.94%

Income Statement

Revenue(ttm)

91.87M

Revenue Per Share(ttm)

Gross Profit(ttm)

82.39M

EBITDA(ttm)³

-111.16M

Net Income Available to Common(ttm)

-138.43M

Diluted EPS(ttm)

-3.15

Share Statistics

Beta (5Y Monthly)

1.08

52-Week Change

-37.34%

S&P 500 52-Week Change

9.20%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

Dividend Yield

0.00%

Float⁴

22.26M

% Held by Insiders

5.10%

% Held by Institutions

91.29%

Balance Sheet

Total Cash(mrq)

196.97M

Total Cash Per Share(mrq)

Total Debt(mrq)

122.11M

Total Debt/Equity(mrq)

-262.84%

Current Ratio(mrq)

5.65%

Quick Ratio(mrq)

8.77%

Book Value Per Share(mrq)

-1.01

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.89

Free Cash Flow(ytd)

-42.07M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

URGN

UroGen Pharma Ltd. Ordinary Shares

UroGen Pharma Ltd. Ordinary Shares Profile